InvivoChem Cat #:V1067CAS #:322-79-2 Purity >=98%Description: Triflusal (formerly UR1501; Disgren, Grendis, Aflen, Triflux), a platelet aggregation inhibitor and a salicylate analog, acts by irreversibly inhibiting the production of thromboxane-B2 in platelets via acetylating the enzyme COX-1/cycloxygenase-1. The main metabolite of Triflusal is HTB, which preserves 6-keto-PGF1alpha synthesis in porcine aortic endothelial cells (PAEC) cells without a significant decline for up to 24 h even at the higher concentration. Triflusal at 10 mM, 100 mM and 1 M decreases LDH efflux in rat brain slices after anoxia/reoxygenation by 24%, 35% and 49% respectively. Triflusal also reduces inducible NO synthase activity by 18%, 21% and 30%.
Description:References: J Thromb Haemost. 2008 Aug; 6(8):1385-92; Eur J Clin Invest. 2000 Sep; 30(9):811-7.
References: